GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AXIM Biotechnologies Inc (OTCPK:AXIM) » Definitions » Revenue

AXIM Biotechnologies (AXIM Biotechnologies) Revenue : $0.04 Mil (TTM As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is AXIM Biotechnologies Revenue?

AXIM Biotechnologies's revenue for the three months ended in Dec. 2023 was $0.01 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.04 Mil. AXIM Biotechnologies's Revenue per Share for the three months ended in Dec. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, AXIM Biotechnologies's highest 3-Year average Revenue per Share Growth Rate was 44.20% per year. The lowest was 44.20% per year. And the median was 44.20% per year.


AXIM Biotechnologies Revenue Historical Data

The historical data trend for AXIM Biotechnologies's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AXIM Biotechnologies Revenue Chart

AXIM Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.06 0.01 0.04

AXIM Biotechnologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Competitive Comparison of AXIM Biotechnologies's Revenue

For the Biotechnology subindustry, AXIM Biotechnologies's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AXIM Biotechnologies's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's Revenue distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's Revenue falls into.



AXIM Biotechnologies Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AXIM Biotechnologies  (OTCPK:AXIM) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


AXIM Biotechnologies Revenue Related Terms

Thank you for viewing the detailed overview of AXIM Biotechnologies's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


AXIM Biotechnologies (AXIM Biotechnologies) Business Description

Traded in Other Exchanges
N/A
Address
6191 Cornerstone Court, E, Suite 114, San Diego, CA, USA, 92121
Axim Biotechnologies Inc is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, it owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications.
Executives
Kurt Phinney officer: Chief Operating Officer 6914 MAGELLAN WAY, SARASOTA FL 34243
Peter O'rourke director C/O NORTHVIEW ACQUISITION CORP., 207 WEST 25TH STREET, 9TH FLOOR, NEW YORK NY 10001
Catalina Valencia 10 percent owner 6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Glycodots, Llc 10 percent owner 6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Juniper & Ivy Corp 10 percent owner 5201 MEMORIAL DRIVE, SUITE 616, HOUSTON TX 77007
Huemoeller John Walter Ii director 305 SAN ANSELMO AVENUE, SUITE 300, SAN ANSELMO CA 94960
Blake Schroeder director 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert L Cunningham director 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Timothy Richard Scott director 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert Malasek officer: CFO PO BOX 235472, ENCINITAS CA 92023
Lekhram Changoer 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Medical Marijuana, Inc. 10 percent owner 12255 CROSTHWAITE CIRCLE, POWAY CA 92064
Van Damme Philip A 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Foundation Sanammad 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
George Anastassov 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022

AXIM Biotechnologies (AXIM Biotechnologies) Headlines

From GuruFocus

AXIM Biotechnologies CEO Issues Letter to Shareholders

By GuruFocusNews GuruFocusNews 04-19-2022